Epclusa for Hep C: Uses, Dosage, Side Effects & Warnings
Apr 12, 2024 · Epclusa treats chronic hepatitis C in adults and children 3+. This once-daily antiviral combines sofosbuvir and velpatasvir to block HCV from multiplying.
Epclusa: Para qué sirve, Dosis y Efectos Secundarios
Información para el paciente sobre Epclusa: para qué sirve, dosis, efectos secundarios y cómo usar este medicamento.
Epclusa Patient Tips: 7 things you should know - Drugs.com
Jul 29, 2025 · Easy-to-read patient tips for Epclusa covering how it works, benefits, risks, and best practices.
Sofosbuvir-velpatasvir (Epclusa): Dosage, Side Effects, Warnings ...
Oct 15, 2024 · Sofosbuvir-velpatasvir (brand name Epclusa) is used to treat chronic hepatitis C (HCV) genotypes 1, 2, 3, 4, 5, or 6 infections in adults and children aged 3 years ...
Epclusa Side Effects: Common, Severe, Long Term - Drugs.com
Aug 19, 2025 · Epclusa side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal …
Epclusa Dosage Guide - Drugs.com
Jun 5, 2024 · Detailed dosage guidelines and administration information for Epclusa (velpatasvir and sofosbuvir). Includes dose adjustments, warnings and precautions.
Epclusa: Package Insert / Prescribing Information / MOA
Jun 24, 2024 · Epclusa package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.
How long is an Epclusa treatment? - Drugs.com
May 27, 2025 · How long is Epclusa treatment if I have a transplanted liver? For people who have had a liver transplant and do not have liver disease or have compensated liver disease (Child-Pugh A), the …
How does Epclusa work in the body? - Drugs.com
Jun 4, 2025 · Epclusa is manufactured by Gilead Sciences Ltd and there a generic version of Epclusa called Velpatasvir and sofosbuvir oral tablets (manufactured by Asegua Therapeutics LLC). Related …
How much does Epclusa cost? - Drugs.com
Jun 5, 2025 · Epclusa is a fixed-dose combination containing sofosbuvir and velpatasvir. An authorized generic version of sofosbuvir and velpatasvir tablets was launched in 2019.